NME2 and neoplasm: Expression of NME2 targets was also increased significantly in high-ColX module PAAD tumors; this protein is a well-established activator of MYC and while competing evidence suggests that it may have pro- or anti-tumor effects in diverse contexts, it has been identified as upregulated in metastatic PDAC samples compared to primary tumors by snRNA-Seq [84].